Agendia Inc. and Paige, are collaborating to co-development treatment planning tools that integrate the cloud-based Paige Platform with genomic information from Agendia’s proprietary MammaPrint and BluePrint diagnostic tests for patients with breast cancer.
These products aim to enable faster access to predictive and prognostic information, from diagnosis and early intervention to metastatic treatment planning.
“Our goal is to provide same-day turnaround in most cases, enable earlier intervention, preserve limited biopsy or surgical tissue specimens, and extend key benefits to physicians and their patients with access to testing in countries where tissue ‘send out’ is not allowed,” Agendia Chief Executive Officer Mark Straley said in a statement.
The initial focus of the collaboration will be the development of digital tests for early treatment planning where genomic testing has played an essential role in determining recurrence risk and tumor biology as doctors and their patients make decisions about the path ahead.
Beyond early intervention, AI-derived biomarkers will be used to augment genomic testing in the metastatic setting, where therapeutic options can add to the complexity of treatment planning.
